RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMOThe ORR of 62% is close to triple the average ORR in mPC which have been reported in historical control trials, suggesting that pelareorep synergizes with PD-L1 inhibitors and standard-of-care chemotherapy in patients with advanced/metastatic pancreatic ductal adenocarcinoma.
By comparison in October 2022, the FDA approved J&J multiple myeloma cancer drug with an ORR of 61.8% at 7.2 months and a duration of response (DOR) of 66.5% at 9 months.
The PDAC arm of ONCYs GOBLET study showed an overall response rate (ORR) of 62%, median progression-free survival of 7.2 months (mPFS), and an interim median overall survival of 10.6 months (iOS).
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma